Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Open accessThe DOI matches its Crossref record; 773 of the 831 references it cites were found in a registry or an index; 177 of the 559 sources its claims cite were checked for support.
Abstract
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments.
Overview
CoChat Summary
TL;DR
This review summarizes current understanding of congenital adrenal hyperplasia (CAH), predominantly 21-hydroxylase deficiency (21OHD), covering steroidogenesis, genetics, diagnosis, management, and long-term outcomes. It emphasizes a phenotypic continuum, newer biomarkers and therapies, and persistent evidence gaps in treatment and surgical care.
Key findings
- 21OHD accounts for approximately 90–99% of CAH; classic CAH incidence is about 1 in 14,000 to 18,000 by newborn screening, while nonclassic (NC) CAH is estimated at ~1 in 200 in the Caucasian population.
- Genotype correlates with the less severely impaired CYP21A2 allele: 96% of individuals with two Group 0 alleles have salt-wasting CAH, whereas 97% of those with at least one Group C allele have NC CAH; residual enzyme activity is ~1–5% in simple virilizing and ~20–50% in NC CAH.
- Long-term sequelae include testicular adrenal rest tumors (TARTs) in males (reported prevalence 14–86%, average 25% in adolescents and 46% in men), adrenal masses in ~20–30% of adults, and increased mortality; adrenal crises caused 42% of deaths in a Swedish cohort, with mean age at death 54.8 years versus 72.8 years in controls.
- Newer concepts include 11-oxo-androgens such as 11-ketotestosterone as biomarkers, the backdoor pathway to dihydrotestosterone, and novel therapies (CRHR1 antagonists, abiraterone, modified-release hydrocortisone, gene/cell-based approaches), though many lack peer-reviewed long-term outcomes.
Methods
- Narrative, multi-authored review resulting from a planned European CAH Symposium postponed due to the COVID-19 pandemic; it covers pathophysiology, diagnostics, management, long-term sequelae, developing-country challenges, and future directions.
- Evidence base is a synthesis of published literature, clinical guidelines (including the 2018 Endocrine Society guideline), registries, observational studies, meta-analyses, and clinical trials; no primary patient cohort or systematic search is described.
- Main analysis is narrative synthesis, with tables and figures summarizing incidence, allele frequencies, treatment dosing, monitoring, and prenatal dexamethasone outcomes.
Limitations
- Stated: there are no large-scale prospective randomized trials for any therapies discussed; evidence is generally low or moderate quality and rests partly on expert opinion, values, and preferences.
- Stated: no evidence-based guidelines for surgical management exist, and there are no studies comparing different feminizing surgery techniques or early versus late surgery; genotype-phenotype correlations are strong but not absolute, and many neuroimaging studies are hindered by small sample size.
- Evident: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or quantitative synthesis; conclusions depend on the cited literature and expert consensus.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
86 Valid · 78 Not valid · 186 Not checked · 76 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Supraphysiological dosages of glucocorticoids similar to those used to treat classic CAH patients may be necessary to suppress adrenal androgen production (426).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Growth
What the sources say
- Disputedcites [426] Livadas, 2019, Management of the female with non-classical congenital adrenal hyperplasia (NCCAH): a patient-oriented approach, Front Endocrinol (Lausanne). sourceExperimental — accuracy not yet measured
In “NCCAH Management From the First Manifestation to the Adult Life” (page unavailable), the paper says glucocorticoids are generally given at replacement, not pharmacological, doses to decrease adrenal androgen production. Its “Management During Childhood” section adds that very high doses are needed to suppress 17-OHP and progesterone, not that supraphysiological doses are necessary to suppress adrenal androgens. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Females do outnumber males in some(12,240,241) although not all (242) retrospective studies in which CAH was clinically diagnosed without neonatal screening.”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [12] Dumic, 2009, Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006, Horm Res. source
- Not checked — no full text of the sourcecites [240] Hird, 2014, No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening, Arch Dis Child. source
- Disputedcites [241] Riedl, 2019, Genotype/phenotype correlations in 538 congenital adrenal hyperplasia patients from Germany and Austria: discordances in milder genotypes and in screened versus prescreening patients, Endocr Connect. sourceExperimental — accuracy not yet measured
Citation (242) is attached to “not all,” offering this study as an example of a retrospectively studied, clinically diagnosed prescreening group without a female majority. The Results (Eligible patients; page unavailable) say the opposite: females made up 64% of the prescreening group. The approximately equal sex distribution was in the screened group, which does not fit that clause. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A single-dose, fixed-sequence study of 8 women given 300 or 600 mg of the CRHR1 antagonist NBI77860 at 2200 (10 PM) showed significant reductions in ACTH and 17OHP over the ensuing 16 hours relative to a control period during which glucocorticoid treatment was withheld (498).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
What the sources say
- Disputedcites [498] Sanders, 2018, Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies, Vet Res Commun. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainstates a causen = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Excessive nighttime glucocorticoid administration has potential adverse metabolic consequences (371,382).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [371] Han, 2013, Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia, Clin Endocrinol (Oxf). source
- Partly supportedcites [382] Whitaker, 2014, An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure, Clin Endocrinol (Oxf). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says cortisol is normally low around midnight and that loss of its rhythm is associated with insulin resistance. It also suggests physiological replacement may help metabolic homeostasis. These passages support a potential metabolic concern, but the paper does not specifically state that excessive nighttime glucocorticoid administration has adverse metabolic consequences. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Low expression of CYP21A2 during the second trimester partially explains the high incidence of false-positives in newborn screens for CAH in premature infants (see section IV.A)(159).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Pattern of CYP21A2 expression
What the sources say
- Could not verifycites [159] Zhou, 1997, Steroid 21-hydroxylase expression and activity in human lymphocytes, Mol Cell Endocrinol. sourceExperimental — accuracy not yet measured
Section 3.1 reports CYP21 expression in cultured lymphoid cells, including cells from CAH patients, but does not examine expression during the second trimester. Searches for premature infants, newborn screening, and false positives found no passage addressing the proposed explanation. (LLM, conf=0.76)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
207 more claims · 72 with their cited sources checked
Create a free account to see all 426 claims and to verify the 50 references still open.
- It may state two separate claims as one. 172
- Probably not a substantial claim. 64
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When combined with complementary methods such MLPA for copy number analysis, it provides nearly complete diagnostic coverage, identifying up to 98-99% of classical pathogenic alleles in most populations (1, 16, 76).”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [76]
In the citing paper
“Although CAH is rare, the most common form is caused by steroid 21-hydroxylase deficiency (21-OHD) and is an autosomal-recessive disorder of adrenal steroidogenesis that results from CYP21A2 mutations.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [1]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Sodium chloride supplements 1-2 g (17-24 mEq/day) in infancy”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Graphical Abstract
Reported 24 · recomputed 34
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“A recent meta-analysis of 48 CAH cases, 34 (71%) described symptomatic improvement after bilateral adrenalectomy but with 34 cases (10%) reporting short-term and 13 cases (27%) long-term adverse outcomes”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
Reported 10 · recomputed 70.833333
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationConsensus Statement on Management of Intersex Disorders
Lee, P. A., Houk, C. P., Ahmed, S. F., Hughes, I. A., & in collaboration with the participants in the International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology (2006) · Pediatrics · doi:10.1542/peds.2006-0738 · Cited by 2,324
Self-citationBornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Self-citationAromatase Cytochrome P450, The Enzyme Responsible for Estrogen Biosynthesis*
SIMPSON, E. R., MAHENDROO, M. S., MEANS, G. D., KILGORE, M. W., HINSHELWOOD, M. M., GRAHAM-LORENCE, S., AMARNEH, B., ITO, Y., FISHER, C. R., MICHAEL, M. D., et al. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-342 · Cited by 1,537
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Self-citation
Research works printed but not linked: 2
- McCann-Crosby, 2014, Non classic CAH; targets of treatment and transition, Pediatr Endocr Rev., 12, 224
- Auchus, 2012, Abiraterone acetate added to physiologic hydrocortisone dosing safely controls androgen excess in adult women with classical 21-hydroxylase deficiency, Endocr Rev., 33, SUN-LB2
Cited by
Items 101–200 of 554
Recent advances in treatments for congenital adrenal hyperplasia
Falhammar, H., Lajić, S., & Nordenström, A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01089-w · Cited by 8
“However, the glucocorticoid dose often needs to be supraphysiological to obtain a satisfactory decrease in androgen levels 1,2 .”
Self-citationApproach of Heterogeneous Spectrum Involving 3beta-Hydroxysteroid Dehydrogenase 2 Deficiency
Nicola, A. G., Carşote, M., Gheorghe, A.-M., Petrova, E. N., Popescu, A. D., Staicu, A. N., Țuculină, M. J., Petcu, C., Dascălu, I. T., & Ţîrcă, T. (2022) · Diagnostics · doi:10.3390/diagnostics12092168 · Cited by 12
Channaiah, C. Y., Memon, S. S., Sarathi, V., Lila, A. R., Barnabas, R., Raghav, D., Bhandare, V. V., Arya, S., Thakkar, H. U., Patil, V. A., et al. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.05.010 · Cited by 8
Blood Pressure in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Balagamage, C., Lawrence, N., Krone, R. E., Bacila, I. A., & Krone, N. P. (2023) · Hormone Research in Paediatrics · doi:10.1159/000533465 · Cited by 13
Self-citationCoker, S. J., Berry, M. J., Vissers, M. C. M., & Dyson, R. M. (2024) · Nutrients · doi:10.3390/nu16030369 · Cited by 8
Clinical spectrum of human STAR variants and their genotype–phenotype correlation
Altınkılıç, E. M., Augsburger, P., Pandey, A. V., & Flueck, C. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0078 · Cited by 10
Sopher, A. B., Oberfield, S. E., & Witchel, S. F. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1735892 · Cited by 14
General infertility workup in times of high assisted reproductive technology efficacy
Polyzos, N. P., Ayoubi, J. M., & Pirtea, P. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.05.019 · Cited by 9
Impact of Newborn Screening on Clinical Presentation of Congenital Adrenal Hyperplasia
Navardauskaitė, R., Banevičiūtė, K., Songailienė, J., Grigalionienė, K., Čereškevičius, D., Šukys, M., Mockevičienė, G., Smirnova, M., Utkus, A., & Verkauskienė, R. (2021) · Medicina · doi:10.3390/medicina57101035 · Cited by 11
“The estimated prevalence of CAH is 1:10,000 and annual incidence ranges from 1: 5000 to 1: 20,000 [1,2].”
BackgroundRapid, accurate long- and short-read mapping to large pangenome graphs with vg GiraffePreprint
Chang, X. H., Novak, A. M., Eizenga, J. M., Sirén, J., Monlong, J., Negi, S., Andreace, F., Nag, S., Kyriakidis, K., Hickey, G., et al. (2025) · Research Square · doi:10.1101/2025.09.29.678807 · Cited by 16
Premature Pubarche: Time to Revise the Diagnostic Approach?
Baronio, F., Marzatico, A., IASIO, R. D., Ortolano, R., Fanolla, A., Radetti, G., Balsamo, A., Pession, A., & Cassio, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062187 · Cited by 7
“) with a measurement of baseline and 60 min serum 17-OHP was performed in all cases to exclude NC21OHD due to 21 hydroxylase deficiency [17,18].”
MethodDiagnóstico prenatal de Hiperplasia adrenal congénita: presentación de un caso
Zayas, N. D., Martínez, Y. E. V., Hernández, D. Q., & Ramírez, M. B. (2023) · Salud Ciencia y Tecnología - Serie de Conferencias · doi:10.56294/sctconf2023164 · Cited by 7
Slob, E. M. A., Termote, J. U. M., Nijkamp, J. W., van der Kamp, H. J., & van den Akker, E. L. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad547 · Cited by 9
Okpaise, O. O., Ahn, H., Tonni, G., & Ruano, R. (2024) · Prenatal Diagnosis · doi:10.1002/pd.6542 · Cited by 10
Genome editing in the adrenal gland: a novel strategy for treating congenital adrenal hyperplasia
van Dijk, E. B., Ginn, S. L., Alexander, I. E., & Graves, L. E. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00011 · Cited by 8
Kendırcı, H. N. P., Ünal, E., Dündar, İ., Buluş, A. D., Güneş, S. O., & Şıklar, Z. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-26-s · Cited by 11
“Both overtreatment and undertreatment adversely affect fertility in both sexes (2,3,10).”
InfluentialA Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia–CYP21A2-R484Q Mutant Mouse
Thirumalasetty, S. R., Schubert, T., Naumann, R., Reichardt, I., Rohm, M.-L., Landgraf, D., Gembardt, F., Peitzsch, M., Hartmann, M. F., Sarov, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105062 · Cited by 8
Self-citation46,XX males with congenital adrenal hyperplasia: a clinical and biochemical description
Adriaansen, B. P. H., Utari, A., Westra, D., Juniarto, A. Z., Ariani, M. D., Ediati, A., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., Drop, S. L. S., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1410122 · Cited by 9
Self-citationCosta, S. T. B., Sampaio, L., Sousa, A. B., Xing, C., Agarwal, A. K., & Garg, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac406 · Cited by 7
Auchus, R. J., Courtillot, C., Dobs, A. S., El‐Maouche, D., Falhammar, H., Lacroix, A., Farrar, M., O’Donoghue, C., Anatchkova, M., Cutts, K. N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1005963 · Cited by 9
“Adding to this challenge is the limited evidence from randomized trial data comparing long-term outcomes of different GCs and GC regimens in adults, leading to a lack of consensus on how to optimize GC therapy (1, 4, 34).”
BackgroundInfluentialSelf-citationImpact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH)
Hoyer‐Kuhn, H., Eckert, A. J., Binder, G., Bonfig, W., Dübbers, A., Riedl, S., Woelfle, J., Dörr, H. G., & Holl, R. W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad307 · Cited by 9
Fanis, P., Skordis, N., Toumba, M., Picolos, M. K., Tanteles, G. A., Neocleous, V., & Phylactou, L. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156616 · Cited by 8
“Congenital adrenal Hyperplasia (CAH) represents a group of autosomal recessive defects each of which is caused by the impairment of several enzymes that are involved in cortisol biosynthesis (1, 2).”
BackgroundEmerging treatment for congenital adrenal hyperplasia
White, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000723 · Cited by 8
Self-citationYan, F., Zeng, J., Chen, Y., Cheng, Y., Yu, P., Zang, L., Chen, K., Gu, W., Du, J., Guo, Q., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03077-w · Cited by 8
Honour, J. W. (2024) · Steroids · doi:10.1016/j.steroids.2024.109502 · Cited by 7
Adrenocortical tumors and hereditary syndromes
Jeyaraman, K., Concolino, P., & Falhammar, H. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2431748 · Cited by 7
“These genetic defects result in cortisol deficiency that stimulates ACTH secretion that in turn results in the adrenocortical hyperplasia [93”
Self-citationBancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
“Antibody-based assays are also commonly used; however, antibody cross-reactivity with structurally related substances can result in overestimation of biomarker levels [4].”
InfluentialNeumann, U., Blankenstein, O., & der Grinten, H. L. C. (2025) · Endocrine Connections · doi:10.1530/ec-24-0619 · Cited by 7
Self-citationApproach to the Patient With a Difference of Sexual Development
Syryn, H., Baere, E. B. W. D., & Cools, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf386 · Cited by 6
Gannarapu, M. R., Nagiri, R. K., Desagoni, M., & Reddy, V. G. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266388061250917093142 · Cited by 9
Lao, Q., Schulman, A., Kulkarni, S., Kollender, S., Bick, D., Moon, A., Burkardt, D. D., & Merke, D. P. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf546 · Cited by 6
Self-citationSimeoli, C., de Angelis, C., Veneri, A. D., Menafra, D., Paola, N. D., Pivonello, C., Somma, C. D., Valerio, P., Melis, D., Alviggi, C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.902844 · Cited by 7
Koren, I., Weintrob, N., Kebesch, R., Majdoub, H., Stein, N., Naor, S., & Segev‐Becker, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad546 · Cited by 6
Free Cortisol and Free 21-Deoxycortisol in the Clinical Evaluation of Congenital Adrenal Hyperplasia
Adriaansen, B. P. H., Utari, A., Olthaar, A. J., van der Steen, R. C. B. M., Pijnenburg-Kleizen, K. J., Berkenbosch, L., Span, P. N., Sweep, F. C. G. J., der Grinten, H. L. C., & van Herwaarden, A. E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae591 · Cited by 7
Self-citationCera, G., Corsello, A., Novizio, R., Donna, V. D., Locantore, P., & Paragliola, R. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111779 · Cited by 8
“Of the classical 21-OHD patients, 75% show a severe mineralocorticoid deficiency with a risk for adrenal crises and are described as salt-wasting (SW) forms, whereas 25% show adequate mineralocorticoid activity and are defined as simple-virilizing [1].”
BackgroundSandberg, D. E., Gardner, M., & Lapham, Z. K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae668 · Cited by 7
Self-citationFertility in differences of sex development patients
Lecoindre, M. C., Finlayson, C. A., & Touraine, P. A. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102017 · Cited by 6
Self-citationHammersen, J. E., Bettendorf, M., Bonfig, W., Schönaü, E., Warncke, K., Eckert, A. J., Fricke‐Otto, S., Palm, K., Holl, R. W., & Woelfle, J. (2022) · Medizinische Genetik · doi:10.1515/medgen-2022-2114 · Cited by 8
“If left untreated, CAH may lead to pseudo-precocious puberty, premature closure of the epiphyses, and short stature [7].”
BackgroundWiromrat, P., Namphaisan, P., Wongsurawat, N., Panamonta, O., & Nasomyont, N. (2022) · Clinical Endocrinology · doi:10.1111/cen.14809 · Cited by 6
“As compared to other forms of adrenal insufficiency, individuals with 21OHD tend to require a higher GC dose for suppressing their adrenal androgen.(1) A previous study has”
BackgroundResultInfluentialCongenital adrenal hyperplasia is a very rare cause of adrenal incidentalomas in Sweden
Sahlander, F., Bensing, S., & Falhammar, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017303 · Cited by 7
“21Hydroxlase is the most common affected enzyme in CAH, which is reported in up to 99% of all cases (15, 18).”
BackgroundMethodInfluentialSelf-citationPharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia
Barra, C. B., Villela, T. R., Soares, N. D. F., Colosimo, E. A., Belisário, A. R., Silva, A. C. S. E., & Silva, I. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279298 · Cited by 6
Kamrath, C., Friedrich, C., Hartmann, M. F., & Wudy, S. A. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106304 · Cited by 7
Self-citationBin, S., Phou, K., & Im, S. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-249997 · Cited by 8
Concolino, P., Perrucci, A., Carrozza, C., & Urbani, A. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00666-x · Cited by 6
“Females with classical 21OHD are usually born with atypical genitalia [4].”
BackgroundNonclassical congenital adrenal hyperplasia: Metabolic and hormonal profile
Piróg, M. M., Pulka, A., Zabiegło, E., & Jach, R. (2023) · Clinical Endocrinology · doi:10.1111/cen.14988 · Cited by 8
Nurses’ Knowledge of Rare Diseases: A Systematic Review
Sánchez, I. M., Martínez‐Linares, J. M., Rodríguez-Blanque, R., Cortés‐Martín, J., Reinoso‐Cobo, A., Carrasco, B. L., & Sánchez-García, J. C. (2025) · Nursing Reports · doi:10.3390/nursrep15090321 · Cited by 8
“A study by Claahsen et al. evaluated multiple registries that examined the integration of training modules on rare diseases into nursing curricula in several European countries [15].”
Tseretopoulou, X., Ali, S., Bryce, J., Amin, N. L., Atapattu, N., Bachega, T. A. S. S., Baronio, F., Ortolano, R., Birkebæk, N., Bonfig, W., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae145 · Cited by 6
“Congenital adrenal hyperplasia (CAH) resulting from 21-hydroxylase deficiency (21-OHD) is the most common genetic cause of adrenal insufficiency (AI) in childhood with a reported worldwide incidence ranging between 1 in 14 000 and 1 in 18 000 births [1].”
BackgroundSelf-citationCongenital Adrenal Hyperplasia
Anisowicz, S. K., & Vogt, K. S. (2025) · Pediatric Annals · doi:10.3928/19382359-20241203-02 · Cited by 7
Strandqvist, A., Asperholm, M., Falhammar, H., Hirschberg, A. L., Nordenström, A., & Herlitz, A. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105748 · Cited by 6
Self-citationAsperholm, M., Strandqvist, A., Falhammar, H., Frankling, K., Åkerlund, I., Laukka, P., Hirschberg, A. L., Nordenström, A., & Herlitz, A. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105747 · Cited by 5
Self-citationNonclassic Adrenal Hyperplasia (NCAH) due to 21-hydroxylase deficiency: A cohort of 78 patients
Wan, Z., Wang, W., Zheng, S., Han, R., Xie, X., Zhao, Y., Wang, W., Sun, S., & Ye, L. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106192 · Cited by 4
Falhammar, H., Hirschberg, A. L., Nordenskjöld, A., Larsson, H., & Nordenström, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad624 · Cited by 5
Self-citationCardiovascular risk in Cuban adolescents and young adults with congenital adrenal hyperplasia
Reyes, T. M. E., Velepucha, A. K. P., Rego, J. O. C., Gómez, W. V., Alonso, E. D., & Falhammar, H. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01499-9 · Cited by 5
Self-citationLandscape of Adrenal Tumours in Patients with Congenital Adrenal Hyperplasia
Carşote, M., Gheorghe, A.-M., Nistor, C., Trandafir, A.-I., Sima, O.-C., Cucu, A.-P., Ciuche, A., Petrova, E. N., & Ghemigian, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11113081 · Cited by 8
Fertility and pregnancy in adrenal insufficiency
Green, D., Dineen, R., O’Reilly, M., & Sherlock, M. (2023) · Endocrine Connections · doi:10.1530/ec-23-0088 · Cited by 13
“In women with CAH, pregnancy outcomes are good with placental aromatase activity protecting the fetus from maternal androgens ( 61 ).”
BackgroundInfluentialWang, Y., Xu, Y., Zhang, H., Yin, D., Pan, Y., He, X., Li, S., Cheng, Z., Zhu, G., Zhao, T., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1267967 · Cited by 8
Presentation and Care for Children with Peripheral Precocious Puberty
Fuqua, J. S., & Eugster, E. A. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.01.006 · Cited by 6
Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia
Ridder, L. O. R., Balle, C. M., Skakkebaek, A. H., Lind‐Holst, M., Nielsen, M. M., Hermann, A. P., Hansen, S., Nielsen, D. G., Knorr, S., Andersen, N. H., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15055 · Cited by 6
“6 A well ‐ known cause of hyperinsulinemia and increased insulin resistance in CAH is overtreatment with corticosteroids, especially in virilized females.”
BackgroundEndoBridge 2023: highlights and pearls
Yıldız, B. O., Boguszewski, C. L., Boguszewski, M. C. D. S., Busetto, L., Celik, O., Fuleihan, G. E., Goulis, D. G., Hammer, G. D., Haymart, M. R., Kaltsas, G., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00549-8 · Cited by 5
“The incidence of classic CAH is approximately 1 in 14,000, whereas nonclassic CAH is more common with a reported incidence of 1 in 200 in American Whites [65].”
Memory in female adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Reyes, T. M. E., Martín, D. C., Álvarez, M. Á., & Falhammar, H. (2024) · Endocrine · doi:10.1007/s12020-024-03806-3 · Cited by 5
Self-citationCongenital adrenal hyperplasia and hypertension
Tosun, B. G., & Güran, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00015-7 · Cited by 6
Challenges in managing disorders of sex development associated with adrenal dysfunction
Finkielstain, G. P., & Rey, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256393 · Cited by 6
Fanis, P., Skordis, N., Phylactou, L. A., & Neocleous, V. (2023) · HORMONES · doi:10.1007/s42000-022-00410-w · Cited by 4
Bizzarri, C., Chioma, L., Bottaro, G., Paone, L., Todisco, T., Chiarito, M., Surace, C., Porzio, O., D’Alessandro, A., Ravà, L., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02581-w · Cited by 7
Altered regional gray matter in Congenital Adrenal Hyperplasia (CAH)
Luders, E., Spencer, D., Gaser, C., Thankamony, A., Hughes, I. A., Srirangalingam, U., Gleeson, H. K., Hines, M. T., & Kurth, F. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105766 · Cited by 6
Lildballe, D. L., Huno, M. R., Ridder, L. O. R., Balle, C. M., Drue, S. O., Berglund, A., Dunø, M., Bak, E. N., Viuff, M. H., Rasmussen, L. S., et al. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02019-8 · Cited by 5
“21-hydroxylase is critical for the biosynthesis of cortisol and aldosterone [2, 3].”
Clinical features, investigation, and management of Addison's disease
Dong, J., Hahner, S., Bancos, I., & Tomlinson, J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00393-6 · Cited by 5
McCann‐Crosby, B., Liang, M. C., Geffner, M. E., Koppin, C. M., Fraga, N. R., Sutton, V. R., Karaviti, L. P., Bhullar, G., & Kim, M. S. (2023) · International Journal of Neonatal Screening · doi:10.3390/ijns9030050 · Cited by 5
Pregnancy in Congenital Adrenal Hyperplasia
Reisch, N., & Auchus, R. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.005 · Cited by 7
Self-citationHe, Z., Dai, H., Shen, J., Huang, Y., Liu, J., Yan, R., Zhang, F., & Yan, S. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05411-9 · Cited by 5
“The diagnosis of congenital adrenal hyperplasia (CAH), an autosomal recessive disorder characterized by enzyme defects in adrenocorticotropic hormone synthesis, in new-borns primarily depends on measuring 17α-OHP levels [3].”
BackgroundWitchel, S. F., Miller, T., McCann, E., & Gupta, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae728 · Cited by 4
Debor, B., Pozza, S. B., Reisch, N., Schmidt, H., & Dubinski, I. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0169 · Cited by 5
Self-citationSteroid profiling in adrenal disease
Mu, D., Sun, D., Qian, X., Ma, X., Qiu, L., Cheng, X., & Yu, S. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117749 · Cited by 6
Dennis, J., Pitts, L. N., Matalka, L., & Mays, L. C. (2024) · Health Care Transitions · doi:10.1016/j.hctj.2024.100057 · Cited by 5
Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity
Barata, I. S., Rueff, J., Kranendonk, M., & Esteves, F. (2024) · Journal of Xenobiotics · doi:10.3390/jox14020034 · Cited by 8
Øzdemir, C. M., Nielsen, M. M., Liimatta, J., Voegel, C. D., Elzenaty, R. N., Wasehuus, V. S., Lind‐Holst, M., Ørnstrup, M. J., Gram, S. B., Ousager, L. B., et al. (2024) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-23-0090 · Cited by 5
Self-citationFylaktou, I., Mertzanian, A., Farakla, I., Gryparis, A., Vasilakis, I. A., Binou, M., Charmandari, E., Kanaka‐Gantenbein, C., & Sertedaki, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100635 · Cited by 6
Navardauskaitė, R., Vanckavičienė, A., & Verkauskienė, R. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1456679 · Cited by 6
Metabolomic Signature in Men with Central Serous Chorioretinopathy Using UHPLC-MS
Durand, S., Zola, M., Bousquet, E., Picard, É., Kowalczuk, L., Zhao, M., Centeno, D., Lyan, B., Brandolini-Bunlon, M., Pujos‐Guillot, E., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00561 · Cited by 5
Borges, J. H., de Oliveira, D. M., de Lemos‐Marini, S. H. V., Geloneze, B., Guerra‐Júnior, G., & Gonçalves, E. M. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06097-w · Cited by 4
Congenital adrenal hyperplasia
Simpson, H., & Hughes, I. A. (2021) · Medicine · doi:10.1016/j.mpmed.2021.05.012 · Cited by 5
Doğruel, D., Turan, İ., Gürbüz, F., Celiloğlu, C., & Yüksel, B. (2022) · HORMONES · doi:10.1007/s42000-022-00354-1 · Cited by 5
Hubska, J., Kępczyńska‐Nyk, A., Czady-Jurszewicz, K., & Ambroziak, U. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020653 · Cited by 8
“It might remain asymptomatic or be misdiagnosed as a different disease [2,7].”
BackgroundInfluentialCurrent Screening Strategies for the Diagnosis of Adrenal Insufficiency in Children
Bowden, S. A. (2023) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s334576 · Cited by 5
The prevalence and genotype of 21-hydroxylase deficiency in the Croatian Romani population
Dumic, K. K., Grubić, Z., Kuŝec, V., Braovac, D., Gotovac, K., Vinković, M., Vučinić, M., & Dumić, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170449 · Cited by 4
“The range of disease manifestations, on the other hand, appears to be a spectrum with no defined boundaries (1).”
BackgroundHuang, R., Chen, Z., Ding, K., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115957 · Cited by 4
Clarke, B. M., Kireta, S., Johnston, J. K., Christou, C., Greenwood, J., Hurtado, P. R., Manavis, J., Coates, P. T., & Torpy, D. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae086 · Cited by 4
Sperm cryopreservation in young males with congenital adrenal hyperplasia (CAH)
Chougar, T., Laanani, M., Ferreux, L., Chalas, C., Wolf, J., Bertherat, J. Y., Bouvattier, C. M., Polak, M., Bachelot, A., Dulon, J., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14792 · Cited by 6
“As previously recommended, patients should be offered semen evaluations and sperm cryopreservation even though some treatments seem to be efficient.(4,7) As TART can appear and develop in childhood, unpredictably, and given its high prevalence in AYA, the risk of severe sperm abnormalities (severe oligozoospermia or c…”
BackgroundSelf-citationClaps, A., Kolomenski, J. E., Fernández, F., Macchiaroli, N., Ingravidi, M. L., Delea, M., Fernández, C., Castro, T., Laiseca, J., Kamenetzky, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-03799-7 · Cited by 3
Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09934-7 · Cited by 4
“Congenital adrenal hyperplasia patients require lifelong cortisol replacement therapy, with hydrocortisone (synthetic cortisol) being the preferred drug for cortisol replacement [ 3, 12].”
InfluentialSevere adrenal insufficiency in six neonates with normal newborn screening for CAH
Kurt, İ., Eser, M., Kahveci, A., Uçar, A., Buluş, D., Özcabı, B., Güran, Ö., Karagözlü, S., Ersoy, A., Demir, S., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15080 · Cited by 4
“1,2 So, it is now performed in an increasing number of countries.”
Lee, Y. J., Cheon, C. K., Suh, J., Ahn, M. B., Ahn, M. B., Chang, S. H., Lee, J. E., Choi, J., Lim, H. H., Kim, J. H., et al. (2024) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448272.136 · Cited by 6
Abawi, O., Sommer, G., Größl, M., Halbsguth, U., du Toit, T., Hannema, S. E., de Bruin, C., Charmandari, E., van den Akker, E. L. T., Leichtle, A. B., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf121 · Cited by 3
Metzger, S., Aebi-Ochsner, C., Busiah, K., Dirlewanger, M., Gschwend, S., Hess, M., Kuhlmann, B., l’Allemand, D., Lang‐Muritano, M., Noordam, C., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf099 · Cited by 4
The Current Treatment Landscape for Congenital Adrenal Hyperplasia
Tonge, J. J., Bacila, I. A., & Krone, N. P. (2025) · Drugs · doi:10.1007/s40265-025-02216-7 · Cited by 4
Self-citationA practical approach to diagnosis and treatment in children with primary adrenal insufficiency
Capalbo, D., Illiano, S., Vasaturo, S., Lorello, P., Rotondo, F. R., Mase, R. D., Bizzarri, C., & Salerno, M. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf229 · Cited by 5
Guo, Z., Xian, P., Green, D., Hu, K., & Yin, L.-M. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157582 · Cited by 3
Fertility in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a review
Roszkowska, Z., Bobrowicz, M., Betlejewska, J., Hubska, J., Rak, B., & Ambroziak, U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1682341 · Cited by 5
Rare forms of congenital adrenal hyperplasia: pathogenesis, clinical, treatment and management
Cavarzere, P., lupieri, V., battiston, R., Mancioppi, V., & Maffeis, C. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02750-x · Cited by 5
Yang, H., Zhang, K., Wang, Y., Liu, S., Guo, Y., Liu, W., Sun, J., Zhang, Z., Zhang, S., Li, S., et al. (2026) · Environmental Science and Ecotechnology · doi:10.1016/j.ese.2026.100663 · Cited by 4
“The CYP450 enzyme family catalyzes oxidative reactions [42], accounting for 70 – 80 % of xenobiotic-metabolizing enzymes critical to drug biotransformation [43,44], and it is involved in PBDE biotransformation, where it alters bioactivity and toxicity [45,46].”
Metadata
- Authors
- Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., Krone, N., Merke, D. P., Miller, W. L., Nordenström, A., Reisch, N., Sandberg, D. E., Stikkelbroeck, N. M. M. L., Touraine, P., Utari, A., Wudy, S. A., & White, P. C.
- Affiliations
- Department of Pediatric Endocrinology, Radboud University Medical Centre, Amalia Childrens Hospital, Nijmegen, The Netherlands
- Northwell Health (US)
- University of Glasgow (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of Michigan (US)
- Karolinska University Hospital (SE)
- University of Bern (CH)
- Queen Mary University of London (GB)
- Technische Universität Dresden (DE)
- Radboud University Medical Center (NL)
- University Hospital Carl Gustav Carus (DE)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of California, San Francisco (US)
- LMU Klinikum (DE)
- Sorbonne Université (FR)
- Diponegoro University (ID)
- Justus-Liebig-Universität Gießen (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- White, Perrin C
- ORCID
- Claahsen - van der Grinten, Hedi L
- Speiser, Phyllis W
- Ahmed, S Faisal
- Arlt, Wiebke
- Auchus, Richard J
- Falhammar, Henrik
- Flück, Christa E
- Guasti, Leonardo
- Huebner, Angela
- Krone, Nils
- Merke, Deborah P
- Miller, Walter L
- Nordenström, Anna
- Reisch, Nicole
- Sandberg, David E
- Touraine, Philippe
- Utari, Agustini
- Wudy, Stefan A
- White, Perrin C
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-05-07
- Volume
- 43
- Issue
- 1
- Pages
- 91-159
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4229036110
- Semantic Scholar
- 1867a4639fab9f23f14102ccc6107c07963e64dc
- Cited by
- 556
- References
- 831
- Citations by year
- 2026: 102 · 2025: 125 · 2024: 149 · 2023: 97 · 2022: 68 · 2021: 14
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (U01-HD083493)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2 mutations, cortisol production, steroidogenic pathway, newborn screening, steroid profiling, genotyping, cell therapy, gene therapy, long-term outcomes, disease registries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.